Sermorelin vs Tesamorelin: GH Peptide Comparison
Sermorelin and Tesamorelin are both GHRH (growth hormone-releasing hormone) analogs that stimulate the pituitary gland to produce growth hormone. Despite sharing the same fundamental mechanism, they differ significantly in regulatory status, clinical evidence, half-life, and cost. Sermorelin is a well-known compounded peptide with decades of use, while Tesamorelin is the only GHRH analog currently holding active FDA approval -- specifically for HIV-associated lipodystrophy.
Side-by-Side Comparison
| Category | Sermorelin | Tesamorelin: GH Peptide Comparison |
|---|---|---|
| Mechanism of action | Synthetic analog of the first 29 amino acids of endogenous GHRH (the full 44-amino-acid hormone). Binds to GHRH receptors on the anterior pituitary to stimulate GH synthesis and pulsatile release. Preserves the natural feedback loop -- GH release is still regulated by somatostatin, preventing supraphysiological spikes. | Synthetic 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification that extends half-life and receptor binding. Stimulates the same GHRH receptors as sermorelin but with greater potency and duration of action due to its structural modifications. |
| Primary research area | Originally FDA-approved (Geref, 1997) as a diagnostic tool for GH deficiency in children and later for GH stimulation. The branded product was discontinued in 2008 for commercial (not safety) reasons. Now widely used as a compounded peptide for age-related GH decline, body composition, and recovery. | FDA-approved (Egrifta, 2010) specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials demonstrated approximately 15% reduction in visceral adipose tissue (VAT) over 26 weeks. Also studied for cognitive function in aging and mild cognitive impairment. |
| Evidence level | Was FDA-approved (now discontinued). Clinical data from the approval era and subsequent studies support its ability to raise GH and IGF-1. Multiple published studies on GH stimulation in adults and children. Extensive real-world use through compounding pharmacies. Safety profile is well-characterized over decades. | Active FDA approval with ongoing post-market surveillance. Phase III trials in HIV lipodystrophy (LIPO-010, LIPO-011) demonstrated statistically significant visceral fat reduction. Nachtigall et al. showed sustained effects over 12 months. Also studied in phase II trials for cognitive decline (Fridman et al.). |
| Administration route | Subcutaneous injection, typically once daily before bed to align with natural GH pulse timing. Short half-life (~10-20 minutes) means timing matters. | Subcutaneous injection, once daily (abdominal). Longer half-life than sermorelin due to structural modifications, though still administered daily. |
| Typical research dosing | 100-300 mcg subcutaneous daily, typically before bed. Some protocols use 5 days on / 2 days off to prevent receptor desensitization. 3-6 month cycles. | 2 mg subcutaneous daily (FDA-approved dose for lipodystrophy). Administered as abdominal injection. Continuous use in clinical trials lasted 26-52 weeks. |
| Key studies/evidence | Original FDA approval data (Geref). Vittone et al. (1997) -- GH stimulation in older adults. Walker (2006) -- review of sermorelin use in age-related GH decline. Decades of clinical use provide extensive safety data, though large modern RCTs are lacking. | Falutz et al. (JAMA, 2007; Ann Intern Med, 2010) -- pivotal trials showing 15% VAT reduction. Nachtigall et al. (2011) -- 12-month durability data. Fridman et al. (2016) -- exploratory cognitive function study in healthy older adults showing improvements in executive function. Stanley et al. -- IGF-1 elevation data. |
Can They Be Stacked?
Combining two GHRH analogs is not recommended. Both bind to the same GHRH receptors on the pituitary, so combining them would not produce synergistic effects -- it would simply increase receptor occupancy and potentially accelerate desensitization. Use one or the other, and consider pairing with a GHRP (like ipamorelin) for synergistic GH release through complementary receptor pathways.
Verdict
Tesamorelin has the stronger clinical evidence profile: active FDA approval, published phase III data, and a specific proven indication (visceral fat reduction in HIV lipodystrophy). Its structural modifications provide greater potency per dose. However, it is significantly more expensive -- often $500-1,500/month at the FDA-approved dose compared to $100-300/month for compounded sermorelin. Sermorelin has decades of clinical use, a well-established safety record, and broad availability through compounding pharmacies at lower cost. For targeted visceral fat reduction, tesamorelin has direct evidence. For general GH support, recovery, and anti-aging protocols, sermorelin offers a cost-effective alternative with a long track record. Neither should be used without monitoring IGF-1 levels.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.